X-ray conglomerate Trex Medical of Danbury, CT, will exhibit forthe first time at an RSNA meeting, with sections of its boothdevoted to the four companies in the Trex universe: Lorad, BennettX-Ray, Continental X-Ray, and XRE. Highlights will include
X-ray conglomerate Trex Medical of Danbury, CT, will exhibit forthe first time at an RSNA meeting, with sections of its boothdevoted to the four companies in the Trex universe: Lorad, BennettX-Ray, Continental X-Ray, and XRE.
Highlights will include Lorad's flagship M-IV mammography system,which began shipping in August, according to Hal Kirshner, presidentand CEO. The system debuted at the 1995 RSNA conference.
Bennett will introduce Contour Plus, the next generation ofits Contour mammography system, which has been upgraded to takepower from the 220-volt outlets common in hospitals, accordingto Bennett president Walter Schneider. In addition to ContourPlus, Bennett will introduce Profile, a new work-in-progress mid-rangefreestanding mammography system designed to fit into smaller roomsthan Contour. Continental will debut a new premium radiography/fluoroscopysystem.
Trex continues to make headway in its efforts to develop afull-field digital mammography detector that can be retrofittedto M-IV, Contour, and Profile systems, according to Kirshner.Trex installed its latest preproduction prototypes at four clinicalsites in September, and will show images from the sites in itsbooth. Data from the sites will be used to support Trex's 510(k)regulatory filing for the system, which should be filed by theend of this year.
What a New Meta-Analysis Reveals About PET/CT Radiotracers for csPCa
February 6th 2025The PET/CT agent 18F-PSMA-1007 offered the highest surface under the cumulative ranking curve (SUCRA) out of nine radiotracers at the patient and lesion level for detecting clinically significant prostate cancer (csPCa), according to a meta-analysis.
New CT Angiography Study Shows Impact of COVID-19 on Coronary Inflammation and Plaque
February 5th 2025Prior COVID-19 infection was associated with a 28 percent higher progression of total percent atheroma volume (PAV) annually and over a 5 percent higher incidence of high-risk plaque in patients with coronary artery lesions, according to CCTA findings from a new study.